BeiGene, Ltd. (6160.HK)
HKD 105.9
(-1.4%)
HKD 105.9
(-1.4%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.07 Billion USD | 506.77% |
| 2022 | -511.06 Million USD | -14.11% |
| 2021 | -447.86 Million USD | 57.62% |
| 2020 | -1.05 Billion USD | -85.28% |
| 2019 | -570.31 Million USD | -11.94% |
| 2018 | -509.49 Million USD | -1330.95% |
| 2017 | -35.6 Million USD | 63.28% |
| 2016 | -96.96 Million USD | -96.15% |
| 2015 | -49.43 Million USD | -460.03% |
| 2014 | -8.82 Million USD | -281.3% |
| 2013 | -2.31 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 791.03 Million USD | 26.22% |
| 2024 Q1 | 626.71 Million USD | 18.57% |
| 2023 Q4 | 528.57 Million USD | -22.84% |
| 2023 Q1 | -42.57 Million USD | 69.47% |
| 2023 Q3 | 684.99 Million USD | 795.34% |
| 2023 Q2 | 76.5 Million USD | 279.71% |
| 2023 FY | 2.07 Billion USD | 506.77% |
| 2022 Q4 | -139.45 Million USD | -20.97% |
| 2022 FY | -511.06 Million USD | -14.11% |
| 2022 Q3 | -115.27 Million USD | -6.93% |
| 2022 Q2 | -107.8 Million USD | 27.41% |
| 2022 Q1 | -148.52 Million USD | 43.96% |
| 2021 Q1 | 252.46 Million USD | 191.3% |
| 2021 Q2 | -242.36 Million USD | -196.0% |
| 2021 Q3 | -192.91 Million USD | 20.4% |
| 2021 FY | -447.86 Million USD | 57.62% |
| 2021 Q4 | -265.05 Million USD | -37.4% |
| 2020 FY | -1.05 Billion USD | -85.28% |
| 2020 Q2 | -234.64 Million USD | 11.92% |
| 2020 Q3 | -279.11 Million USD | -18.95% |
| 2020 Q4 | -276.51 Million USD | 0.93% |
| 2020 Q1 | -266.39 Million USD | -9.02% |
| 2019 Q1 | -115.77 Million USD | 44.33% |
| 2019 FY | -570.31 Million USD | -11.94% |
| 2019 Q2 | -3.25 Million USD | 97.19% |
| 2019 Q3 | -206.93 Million USD | -6261.3% |
| 2019 Q4 | -244.35 Million USD | -18.08% |
| 2018 FY | -509.49 Million USD | -1330.95% |
| 2018 Q4 | -207.98 Million USD | -103.72% |
| 2018 Q3 | -102.09 Million USD | 13.26% |
| 2018 Q2 | -117.7 Million USD | -44.06% |
| 2018 Q1 | -81.7 Million USD | -7.23% |
| 2017 Q2 | -47.24 Million USD | -10.46% |
| 2017 Q1 | -42.77 Million USD | -47.83% |
| 2017 FY | -35.6 Million USD | 63.28% |
| 2017 Q4 | -76.19 Million USD | -158.34% |
| 2017 Q3 | 130.6 Million USD | 376.45% |
| 2016 FY | -96.96 Million USD | -96.15% |
| 2016 Q2 | -20.72 Million USD | -20.49% |
| 2016 Q4 | -28.93 Million USD | 3.9% |
| 2016 Q3 | -30.1 Million USD | -45.27% |
| 2016 Q1 | -17.2 Million USD | 26.58% |
| 2015 Q4 | -23.42 Million USD | -95.69% |
| 2015 FY | -49.43 Million USD | -460.03% |
| 2015 Q1 | -8.68 Million USD | -79.82% |
| 2015 Q2 | -5.35 Million USD | 38.28% |
| 2015 Q3 | -11.97 Million USD | -123.46% |
| 2014 Q2 | -1.04 Million USD | 0.0% |
| 2014 Q3 | -1.91 Million USD | -84.25% |
| 2014 Q1 | -1.04 Million USD | 0.0% |
| 2014 FY | -8.82 Million USD | -281.3% |
| 2014 Q4 | -4.82 Million USD | -151.67% |
| 2013 FY | -2.31 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 392.81 Million HKD | -429.217% |
| CK Life Sciences Int'l., (Holdings) Inc. | 947.7 Million HKD | -119.357% |